Technical Analysis for ABUS - Arbutus Biopharma Corporation

Grade Last Price % Change Price Change
D 3.44 -1.43% -0.05
ABUS closed down 1.43 percent on Wednesday, November 20, 2024, on 59 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Down Down

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
Stochastic Reached Oversold Weakness 0.00%
Gapped Up Strength 0.00%
Down 3 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Hammer Candlestick Bullish -1.43%
NR7 Range Contraction -1.43%
Lower Bollinger Band Walk Weakness -1.43%
Lower Bollinger Band Touch Weakness -1.43%
Oversold Stochastic Weakness -1.43%

   Recent Intraday Alerts

Alert Time
Down 2 % about 17 hours ago
Possible NR7 about 18 hours ago
Down 1% about 18 hours ago
Lower Bollinger Band Support about 19 hours ago
60 Minute Opening Range Breakdown about 21 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Arbutus Biopharma Corporation Description

Arbutus Biopharma Corporation, a biopharmaceutical company, focuses on the research and development of RNA interference therapeutics, and provides lipid nanoparticle delivery technology to pharmaceutical partners in Canada. The company's products for Hepatitis B virus (HBV) comprise TKM-HBV, a RNAi therapeutic in Phase I clinical trial; OCB-030, a cyclophilin inhibitor drug candidate; CYT-003, a TLR9 agonist; capsid assembly inhibitors for use as oral therapeutics; surface antigen secretion inhibitors; STING agonists, a stimulator of interferon genes research program; cccDNA formation inhibitors for reducing the amount of cccDNA in the infected liver cell; and cccDNA epigenetic modifiers, a research program to inhibit the formation of new virus and subviral particles from cccDNA. Its products also include TKM-PLK1, an oncology product platform that is in Phase I/II clinical trials for the treatment of gastrointestinal neuroendocrine tumors, adrenocortical carcinoma, and hepatocellular carcinoma; TKM-Ebola, an anti-ebola viral therapeutic in Phase I clinical trial; and TKM-Ebola-Guinea, an anti-ebola RNAi therapeutic in Phase 2 trial. In addition, the company develops TKM-Marburg to treat Marburg infections; TKM-HTG, a multi-component RNAi therapeutic that targets a combination of genes expressed in the liver, which play a role in triglyceride metabolism; and TKM-ALDH, an aldehyde dehydrogenase to induce long term acute sensitivity to ethanol to treat severe alcohol use disorder. Further, its partnered programs consists of ALN-TTR02, a therapeutic targeting transthyretin amyloidosis; ALN-VSP for liver cancer; ALN-PCS02 for hypercholesterolemia; Marqibo for Philadelphia chromosome-negative acute lymphoblastic leukemia; and DCR-PH1 for primary hyperoxaluria type 1. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in August 2015. Arbutus Biopharma Corporation is headquartered in Burnaby, Canada.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Alcohol Infectious Diseases Gastrointestinal Hydrogen Hepatitis B Lipid Cholesterol Metabolism Carcinoma Amyloid Amyloidosis Hepatitis B Virus Hepatocellular Carcinoma Interferon Hypercholesterolemia Rna Interference Acute Lymphoblastic Leukemia Cyclophilin Ebola Liver Cancer Neuroendocrine Tumors Transthyretin Neuroendocrine Tumor PLK1 Pharmaceutical Partners Triglyceride Tropical Diseases Zoonoses Sexually Transmitted Diseases And Infections Tlr9 Transthyretin Amyloidosis

Is ABUS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.725
52 Week Low 1.79
Average Volume 1,065,882
200-Day Moving Average 3.38
50-Day Moving Average 3.92
20-Day Moving Average 3.79
10-Day Moving Average 3.62
Average True Range 0.15
RSI (14) 29.08
ADX 29.16
+DI 10.65
-DI 28.08
Chandelier Exit (Long, 3 ATRs) 3.66
Chandelier Exit (Short, 3 ATRs) 3.88
Upper Bollinger Bands 4.17
Lower Bollinger Band 3.41
Percent B (%b) 0.04
BandWidth 20.04
MACD Line -0.12
MACD Signal Line -0.09
MACD Histogram -0.0389
Fundamentals Value
Market Cap 576.87 Million
Num Shares 168 Million
EPS -0.46
Price-to-Earnings (P/E) Ratio -7.48
Price-to-Sales 21.53
Price-to-Book 3.88
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.62
Resistance 3 (R3) 3.63 3.59 3.59
Resistance 2 (R2) 3.59 3.54 3.58 3.58
Resistance 1 (R1) 3.51 3.51 3.49 3.50 3.57
Pivot Point 3.47 3.47 3.45 3.46 3.47
Support 1 (S1) 3.39 3.42 3.37 3.38 3.31
Support 2 (S2) 3.35 3.39 3.34 3.30
Support 3 (S3) 3.27 3.35 3.29
Support 4 (S4) 3.26